Advanced search
Publication Cover
Immunological Medicine Volume 45, 2022 - Issue 4
Submit an article Journal homepage
1,627
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Immune response induced in rodents by anti-CoVid19 plasmid DNA vaccine via pyro-drive jet injector inoculation

Tomoyuki Nishikawaa Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, Osaka, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3289-0912View further author information
ORCID Icon,
Chin Yang Changa Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, Osaka, JapanView further author information
,
Jiayu A. Taia Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, Osaka, JapanView further author information
,
Hiroki Hayashib Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Osaka, JapanView further author information
,
Jiao Sunb Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Osaka, JapanView further author information
,
Shiho Toriic Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, JapanView further author information
,
Chikako Onoc Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, JapanView further author information
,
Yoshiharu Matsuurac Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, JapanView further author information
,
Ryoko Ided FunPep Co., Ltd, Tokyo, JapanView further author information
,
Junichi Minenoe Takara Bio Inc, Shiga, JapanView further author information
,
Miwa Sasaif Department of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan;g Laboratory of Immunoparasitology, WPI Immunology Frontier Research Center, Osaka University, Osaka, JapanView further author information
,
Masahiro Yamamotof Department of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan;g Laboratory of Immunoparasitology, WPI Immunology Frontier Research Center, Osaka University, Osaka, JapanView further author information
,
Hironori Nakagamib Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Osaka, JapanView further author information
&
Kunihiko Yamashitaa Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, Osaka, Japan;h Medical Device Research, Industry Business Unit, Daicel Corporation, Osaka, JapanView further author information
 show all
Pages 251-264 | Received 09 Jun 2022, Accepted 05 Aug 2022, Published online: 24 Aug 2022

References

  • Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62–84.
  • Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
  • Chang C, Sun J, Hayashi H, et al. Stable immune response induced by intradermal DNA vaccination by a novel needleless pyro-drive jet injector. AAPS PharmSciTech. 2020;21(1):19.
  • Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114.
  • Hayashi H, sun j, Yanagida Y, et al. Preclinical study of DNA vaccines targeting SARS-CoV-2. Curr Res Transl Med. 2022;70(4):103348.
  • Miyazaki H, Atobe S, Suzuki T, et al. Development of pyro-drive jet injector with controllable jet pressure. J Pharm Sci. 2019;108(7):2415–2420.
  • Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020;117(13):7001–7003.
  • Torii S, Ono C, Suzuki R, et al. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 2021;35(3):109014.
  • Dinnon KH, 3rd, Leist SR, Schäfer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–566.
  • Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
  • Bukowska A, Spiller L, Wolke C, et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp Biol Med. 2017;242(14):1412–1423.
  • Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–733.e11.
  • Dieterle ME, Haslwanter D, Bortz RH, 3rd, et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe. 2020;28(3):486–496.e6.
  • Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
  • Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488.
  • Palacios R, Patiño EG, de Oliveira Piorelli R, et al. Double-Blind, randomized, Placebo-Controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853.
  • Armengaud J, Delaunay-Moisan A, Thuret JY, et al. The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19. Environ Microbiol. 2020;22(6):1997–2000.
  • Fidel PL, Jr., Noverr MC. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? mBio. 2020;11(3):e00907-20.
  • Ghorbani A, Zare F, Sazegari S, et al. Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. New Microbes New Infect. 2020;38:100786.
  • Pushko P, Tretyakova I. Influenza virus like particles (VLPs): opportunities for H7N9 vaccine development. Viruses. 2020;12(5):518.
  • Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - Preliminary report. N Engl J Med. 2020;383(20):1920–1931.
  • Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438.
  • Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601.
  • Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806–811.
  • Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–788.
  • Hettinga J, Carlisle R. Vaccination into the dermal compartment: techniques, challenges, and prospects. Vaccines. 2020;8(3):534.
  • Tebas P, Kraynyak KA, Patel A, et al. Intradermal SynCon® ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers. J Infect Dis. 2019;220(3):400–410.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.